Introduction {#Sec1}
============

Glycylcyclines are molecules that have structural similarities to tetracyclines but are active against tetracycline-resistant organisms. Tigecycline, the first glycylcycline discovered, was approved by the Food and Drug Administration in June 2005 and entered the Chinese market in November 2011. It has been widely used since 2015 \[[@CR1]\] and requires intravenous administration with a loading dose of 100 mg followed by 50 mg twice daily. Tigecycline has broad-spectrum activity; it inhibits protein synthesis by acting on the 30S ribosomal subunit, blocking entry of aminoacyl-transfer ribonucleic acid (RNA) molecules into the ribosome site \[[@CR2]\]. Tigecycline is active against resistant pathogens such as methicillin-resistant staphylococci, penicillin-resistant *Streptococcus pneumoniae*, and vancomycin-resistant enterococci \[[@CR3]\]. The main indications for tigecycline are complicated intra-abdominal infection, complicated skin and skin-and-soft-tissue infection, and community-acquired pneumonia caused by bacteria sensitive to tigecycline.

Although tigecycline was generally well tolerated in registry trials, its introduction and widespread use have resulted in reports of adverse reactions. The most frequent are nausea, vomiting, diarrhoea, abdominal pain, headache, and an increased alanine aminotransferase level. Less frequent adverse events include increased alkaline phosphatase and total bilirubin levels, prolonged prothrombin time (PT) and activated partial thromboplastin time (APTT), and pancreatitis \[[@CR3]--[@CR5]\]. Among patients who received tigecycline during clinical trials, \< 2% developed coagulopathy \[[@CR6]\]. However, only six case reports \[[@CR4], [@CR7]--[@CR11]\] and two clinical studies \[[@CR5], [@CR12]\] performed from 2000 to 2019 have focused on patients who developed hypofibrinogenaemia after tigecycline use, as indicated by an increased international normalized ratio (INR) and prolonged PT and APTT; in these cases, the hypofibrinogenaemia resolved after tigecycline discontinuation.

As high rates of treatment failure among patients treated with the standard of dose tigecycline have been documented \[[@CR13]--[@CR15]\], combination therapy and high-dose tigecycline are the options chosen by many physicians when facing severe infections caused by drug-resistant pathogens. Dong et al. \[[@CR16]\] reported that combinations of rifampin/tigecycline and sulbactam/tigecycline show good in vitro activity against extensively drug-resistant *Acinetobacter baumannii* strains. Another in vitro study revealed that combination therapies (tigecycline/colistin and tigecycline/sulbactam) could achieve lower mutant prevention concentrations (MPCs) of tigecycline than tigecycline use alone \[[@CR17]\]. A review showed that tigecycline plus sulbactam, carbapenem, or rifampicin showed synergistic effects against different bacteria \[[@CR18]\]. Cefoperazone/sulbactam, the combination of a third-generation cephalosporin and a β-lactamase inhibitor, is mostly used in China to treat severe bacterial infections and as a combination therapy with tigecycline to treat drug-resistant pathogens. It has low renal toxicity and high safety levels \[[@CR19]\], but long-term high-dose use may lead to vitamin K--dependent coagulation dysfunction. Hu \[[@CR20]\] reported a fatal vitamin K--dependent coagulopathy associated with cefoperazone/sulbactam in a 79-year-old man with normal coagulation function and no history of blood or liver disease. However, whether cefoperazone/sulbactam combined with tigecycline aggravates coagulopathy or hypofibrinogenaemia is unclear.

We retrospectively analyzed the risk factors and clinical features of tigecycline-associated hypofibrinogenaemia and the coagulation function of hypofibrinogenaemic patients treated or not with cefoperazone/sulbactam.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

This retrospective case--control study was conducted at the First Affiliated Hospital of the Medical College of Zhejiang University, a 2500-bed tertiary-care teaching hospital, from January 1, 2017, to December 31, 2017. The hospital has a 73-bed intensive care unit (ICU), comprising a 29-bed medical ICU, a 15-bed emergent ICU, and a 29-bed surgical ICU. Patients with severe sepsis (according to sepsis 3.0) and treated with tigecycline (treatment for more than 3 days) were included in the study. All enrolled patients were greater than 18 years old, and the fibrinogen level before the use of tigecycline was greater than 2.0 g/L. Pregnant women and patients with incomplete medical records who received anticoagulant therapy or exogenous fibrinogen during treatment with tigecycline were excluded from the study. Patients who developed hypofibrinogenaemia after tigecycline treatment were included in the hypofibrinogenaemia (\< 2.0 g/L) group, and the remaining patients were included in the normal fibrinogen group (≥ 2.0 g/L; normal group). Hypofibrinogenaemia was diagnosed if the fibrinogen level was \< 2 g/L for two consecutive days. The selection of patients is depicted in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1The detailed patient selection process. ICU intensive care unit, FIB fibrinogen, CPZ/SAM cefoperazone/sulbactam

Data collection {#Sec4}
---------------

The sex, age, and comorbidities of the study population were evaluated. The following parameters were also assessed at the time of tigecycline initiation: Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II scores, fibrinogen level, organ function (cardiac insufficiency, respiratory failure, shock, acute kidney injury, continuous renal replacement therapy, and liver function), infection indices (white blood cells, neutrophils, procalcitonin (PCT), and C-reactive protein (CRP)), sites of infection (bloodstream, lung, cranium, abdomen, skin, or urinary tract), use of empirical antifungal therapy, presence of pathogenic microorganisms (*Acinetobacter baumannii*, *Klebsiella pneumoniae*, *Burkholderia cepacia*, *Stenotrophomonas maltophilia*, or others), and therapeutic regimen (loading dose of 50 mg, 100 mg, or more than 100 mg; maintenance dose of 50 mg Q12H, 100 mg Q12H, or 50 mg Q12H and 100 mg Q12H; treatment duration; and combination therapy of cefoperazone/sulbactam or sodium valproate). The incidence of common complications (coagulopathy, blood-product infusion, jaundice, severe bleeding) and the overall prognosis (length of ICU stay after starting tigecycline; total length of ICU stay, and 28-day ICU mortality rate) were also compared between the two groups.

To further analyze the effect of cefoperazone/sulbactam on coagulation in the hypofibrinogenaemia group, the minimum fibrinogen level, the time to hypofibrinogenaemia, and the time from discontinuation of tigecycline to normalization of the fibrinogen level were evaluated. Coagulopathy, jaundice, severe bleeding, and blood-product infusion were also compared between patients in the hypofibrinogenaemia group treated or not with cefoperazone/sulbactam.

Definitions {#Sec5}
-----------

Liver dysfunction was defined as a serum bilirubin level of \> 3 mg/dL and/or with a prothrombin time (PT) of \< 50%, except in patients with jaundice, in whom it was defined as an increase in the serum bilirubin level or a PT of \< 50% \[[@CR21]\]. Kidney failure was defined as the criteria for stage 3 according to the Acute Kidney Injury Network (AKIN), which is an increase in serum creatinine (SCr) of more than 300% (\> 3-fold) from baseline or serum creatinine of more than or equal to 4.0 mg/dL (≥ 354 μmol/L) with an acute increase of at least 0.5 mg/dL (44 μmol/L) or urine output less than 0.3 mL/kg per hour for 24 h or anuria for 12 h \[[@CR22]\]. Cardiac insufficiency was defined as the New York College of Cardiology classes II--IV. Acute kidney injury was defined according to the 2012 KDIGO (Kidney Disease: Improving Global Outcomes) Clinical Practice Guidelines for Acute Kidney Injury as any of the following: an increase in the SCr of ≥ 0.3 mg/dL (≥ 26.5 μmol/L) within 48 h, an increase in the SCr to ≥ 1.5-fold of the baseline value known or presumed to have occurred within the prior 7 days, or a urine volume of \< 0.5 mL/kg/h for 6 h. Coagulopathy was defined as an INR of \> 1.5 or an APTT of \> 60 s \[[@CR23]\]. Multiple drug resistance (MDR) is defined as non-susceptibility to at least one agent in three or more antimicrobial categories. Extensively drug-resistant bacteria (XDR) are defined as being non-susceptible to at least one agent in all but two or fewer antimicrobial categories (i.e., bacterial isolates remain susceptible to only one or two categories) \[[@CR24]\].

Statistical analysis {#Sec6}
--------------------

Statistical analysis was performed using Statistical Package for Social Sciences ver. 19.0. Continuous variables are presented as the mean ± standard deviation (SD) (normal distribution) or as medians and interquartile range (non-normal distribution) and were evaluated by the *t* test or Mann--Whitney *U* test, as appropriate. A chi-squared test was used for categorical variables, and univariate and multivariate analyses were performed using logistic regression models to identify independent risk factors for tigecycline-associated hypofibrinogenaemia. All biologically plausible variables significant at *p* \< 0.10 in univariate analyses were entered into a multivariate forward logistic regression analysis. A *p* value \< 0.05 was considered to indicate statistical significance.

Results {#Sec7}
=======

Demographics of the study population {#Sec8}
------------------------------------

During the study period, 127 critically ill patients with severe infections treated with tigecycline in the medical, surgical, or emergent ICU were enrolled. With the exception of 16 patients who were treated with empirical antibacterial therapy, the patients were infected with drug-resistant bacteria (multiple drug resistant (MDR) or extensively drug resistant (XDR)). Of these patients, 71 (56%) developed hypofibrinogenaemia and were placed in the hypofibrinogenaemia group, and the other 56 were placed in the normal fibrinogen group (≥ 2.0 g/L; normal group). The mean ages of the patients in the hypofibrinogenaemia and normal groups were 63.72 ± 15.68 and 55.82 ± 18.59 years, respectively (*p* = 0.061). Males accounted for 79% of the patients (77.5% in the hypofibrinogenaemia group and 80.4% in the normal group, *p* = 0.692). There was no significant difference in the prevalence of chronic obstructive pulmonary disease, hypertension, diabetes mellitus, coronary heart disease, arrhythmia, solid organ tumour, autoimmune disease, cerebrovascular accident, liver failure, chronic renal failure, or surgery between the hypofibrinogenaemia and normal groups (Table [1](#Tab1){ref-type="table"}).Table 1Demographics of the study populationVariableHypofibrinogenaemia groups (*n* = 71)Normal groups (*n* = 56)OR95% CI*p*Age (years) (mean ± SD)63.72 ± 15.6855.82 ± 18.590.061Sex (male, *n* (%))55 (77.5)45 (80.4)0.8400.355--1.9910.692COPD (%)10 (14.1)3 (4.5)2.8960.757--11.0790.107Hypertension (%)31 (43.7)25 (44.6)0.9610.475--1.9460.912DM (%)17 (23.9)16 (28.6)0.7870.355--.7440.555CHD (%)5 (7)7 (12.5)0.5300.159--1.7710.296Arrhythmia (%)10 (14.1)4 (7.1)0.4690.139--1.5850.215Solid organ tumour (%)19 (26.8)11 (19.6)0.6690.288--1.5540.348Autoimmune disease^\#^ (%)4 (5.6)5 (8.9)1.6420.420--6.4260.711Cerebrovascular accident (%)13 (18.3)10 (17.9)1.0310.415--2.5630.948Chronic liver disease\* (%)5 (7)2 (3.6)2.0450.382--10.9620.464Chronic renal failure^\#^ (%)4 (5.6)6 (10.7)0.4980.133--1.8570.469Surgery in the past medical history^&^ (%)35 (49.3)23 (41.1)1.3950.688--2.8290.356\*Fisher's exact test, ^\#^continuity correction chi-square test, and ^&^history of surgery and non-invasive procedures, such as endoscopy or colonoscopy, are excluded from this category*OR* odds ratio, *CI* confidence interval, *COPD* chronic obstructive pulmonary disease, *DM* diabetes mellitus, *CHD* coronary heart disease

Clinical features of patients with hypofibrinogenaemia {#Sec9}
------------------------------------------------------

In the hypofibrinogenaemia group, hypofibrinogenaemia developed 1 to 25 days after the initiation of tigecycline, with a median (25--75th percentile) of 6 (4--8) days (Fig. [2](#Fig2){ref-type="fig"}). Among the patients in the hypofibrinogenaemia group, 51 (72%) patients discontinued tigecycline treatment (due to medical improvement, drug resistance, economic position, serious complications, or other factors). Among these patients, the fibrinogen level did not return to the normal range in two patients, and seven patients had incomplete data; the fibrinogen level of the remaining 42 (42/51, 82%) patients normalized within a median of 3 (3--5) days (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2The distribution of time (days) from tigecycline use to hypofibrinogenaemia in hypofibrinogenaemia group. Patients developed hypofibrinogenaemia from 1 to 25 days after initiation of tigecycline, with a median (25--75th percentile) of 6 (4--8) days in the hypofibrinogenaemia group (*n* = 71)Fig. 3The distribution of time (days) to recover to level of fibrinogen after the discontinuation of tigecycline in hypofibrinogenaemia group. Fifty-one patients discontinued tigecycline treatment in hypofibrinogenaemia group. Fibrinogen level did not return to the normal range in two patients and seven patients had incomplete data; the fibrinogen level of the remaining 42 (82%) patients normalized within a median of 3 (3--5) days

Risk factors for hypofibrinogenaemia {#Sec10}
------------------------------------

The risk factors for hypofibrinogenaemia are listed in Table [2](#Tab2){ref-type="table"}. In univariate analyses, the development of hypofibrinogenaemia was significantly associated with the fibrinogen level before starting tigecycline (3.91 ± 1.41 g/L in the hypofibrinogenaemia group vs. 5.27 ± 1.90 g/L in the normal group, *p* \< 0.001), intra-abdominal infection (*p = 0.008*), and therapeutic regimen (initial dose, maintenance dose, and treatment duration), but not the SOFA or APACHE II scores, organ function, infection indices, other infection sites (bloodstream, lung, cranium, skin, or urinary tract), use of empirical antibacterial therapy, and pathogenic microorganisms at the time of tigecycline initiation. A loading dose of 50 mg (16.9% (12) patients in the hypofibrinogenaemia group vs. 32.1% (18) in the normal group, *p* = 0.045) and a maintenance dose of 50 mg Q12H (33 (46.5%) vs. 38 (67.9%), *p* = 0.016) protected against hypofibrinogenaemia. The median tigecycline duration in the hypofibrinogenaemia group was 11 (8--16) days, significantly longer than that in the normal group, or 6 (3--16.75 days, *p* = 0.001). However, combination therapies, cefoperazone/sulbactam (*p* = 0.286) and sodium valproate (*p* = 0.696), were used in similar proportions of patients in the two groups.Table 2Univariate analysis of risk factors for tigecycline-associated hypofibrinogenaemiaVariableHypofibrinogenaemia groups (*n* = 71)Normal groups (*n* = 56)OR95% CI*p*Index when starting to use tigecycline  SOFA scores9.54 ± 6.2010.95 ± 7.230.9690.919--1.0210.239  APACHE II scores11.82 ± 6.2011.95 ± 7.990.9970.949--1.0490.055  Fibrinogen level (g/L)3.92 ± 1.415.27 ± 1.900.6011.465--0.775\< 0.001Organ function when starting to use tigecycline  Cardiac insufficiency (%)1 (1.4)4 (7.1)0.1860.020--1.7110.137  Respiratory failure (%)61 (85.9)50 (89.3)0.7320.249--2.1530.571  Shock (%)27 (38)21 (37.5)1.0230.496--2.1070.951  KidneyAKI (%)30 (42.3)22 (39.3)1.1310.554--2.3090.736CRRT (%)20 (28.2)14 (25)1.1760.531--2.6070.689  LiverALB (g/L)32.84 ± 4.6431.82 ± 5.191.0440.969--1.1260.254TB (μmol/L)16.5 (10.25--32.25)14.5 (10--24.75)0.9990.991--1.0080.892DB (μmol/L)10 (5--21.51)7 (4.25--13.75)0.9990.988--1.0110.909INR1.25 (1.15--1.36)1.1 (1.10--1.30)1.3690.383--4.8940.629Infection index when starting to use tigecycline  WBC (× 10E9)\< 4 (%)6 (8.5)2 (3.5)0.6070.285--1.2920.1954--10 (%)28 (39.4)17 (30.4)\> 10 (%)37 (52.1)37 (66.1)  Neutrophil (%)88.03 ± 6.7785.602 ± 9.171.0400.993--1.0900.095  CRP (mg/L)117.34 ± 69.03131.56 ± 108.220.9980.994--1.0020.371  PCT (ng/mL)1.15 (0.49--4.98)0.7 (0.36--2.82)1.0080.981--1.0360.552Infected site  Bloodstream infection (%)25 (35.2)16 (28.6)1.3590.637--2.8970.428  Pneumonia (%)46 (64.8)39 (69.6)0.8020.379--1.6970.564  Intracranial infection (%)4 (5.6)4 (7.1)0.7760.185--3.2510.729  Intra-abdominal infection (%)16 (22.5)2 (3.6)7.8551.723--35.8110.008  Skin infection (%)2 (2.8)4 (7.1)0.3770.066--2.1360.270  Urinary tract infection (%)5 (7)3 (5.4)1.3380.306--5.8580.699  Empirical antibacterial therapy (%)6 (8.5)10 (17.9)0.4250.144--1.2510.120  Two or more than (%)27 (38)20 (35.7)1.1050.534--2.2850.789Pathogenic microorganism  *Acinetobacter baumannii* (%)28 (39.4)27 (48.2)0.6990.345--1.4200.322  *Klebsiella pneumoniae* (%)34 (47.9)28 (50)0.9190.456--1.8520.813  *Burkholderia cepacia* (%)5 (7)4 (7.1)0.9850.252--3.8530.982  *Pseudomonas maltophilia* (%)6 (8.5)2 (3.6)2.4920.483--12.8550.275  Others (%)24 (33.8)12 (21.4)1.8720.836--4.1910.124  Two or more than (%)23 (41.1)24 (33.8)0.7330.355--1.5120.400Therapeutic regimen  Loading dose50 mg (%)12 (16.9)18 (32.1)0.4290.186--0.9910.045100 mg or more than (%)59 (83.1)38 (67.9)2.3761.009--5.3760.045  Maintenance dose50 or 100 mg Q12H (%)16 (22.5)6 (10.7)2.4240.880--6.6790.08150 mg Q12H (%)33 (46.5)38 (67.9)0.4110.198--0.8530.016100 mg Q12H (%)22 (31)12 (21.4)1.6460.730--3.7110.227  Maintenance dose50 mg Q12H (%)33 (46.5)38 (67.9)1.7521.066--2.8780.027100 mg Q12H (%)22 (31)12 (21.4)50 or 100 mg Q12H (%)16 (22.5)6 (10.7)  Treatment duration11 (8--16)6 (3--16.75)1.1211.046--1.2020.001  Combination therapySodium valproate (%)5 (7)5 (8.9)0.7730.212--2.8140.696CPZ/SAM (%)30 (42.3)29 (51.8)0.6810.337--1.3780.286*OR* odds ratio, *CI* confidence interval, *SOFA* Sequential Organ Failure Assessment, *APACHE* Acute Physiology and Chronic Health Evaluation, *AKI* acute kidney injury, *CRRT* continuous renal replacement therapy, *ALB* albumin, *ALT* alanine transaminase, *TB* total bilirubin, *DB* direct bilirubin, *INR* international normalized ratio, *WBC* white blood cells, *CRP* C-reactive protein, *PCT* procalcitonin, *CPZ/SAM* cefoperazone/sulbactam

The following variables that were significant at *p* \< 0.10 in the univariate analyses were included in the multivariate analysis: fibrinogen level, APACHE II scores, neutrophil count, presence of intra-abdominal infection, loading dose, maintenance dose, and treatment duration. In the multivariate analysis, the presence of intra-abdominal infection (*p* = 0.005), fibrinogen level (*p* \< 0.001), maintenance dose (*p* = 0.039), and treatment course (*p* = 0.002) were related to hypofibrinogenaemia (Table [3](#Tab3){ref-type="table"}).Table 3Multivariate analysis of risk factors for tigecycline-associated hypofibrinogenaemiaVariableOR95% CI*p*Maintenance dose1.9981.037--3.8490.039Treatment course1.1521.053--1.2600.002Fibrinogen level when staring to use tigecycline0.5580.414--0.752\< 0.001Intra-abdominal infection11.4202.069--63.0500.005*OR* odds ratio, *CI* confidence interval

Clinical complications and outcomes {#Sec11}
-----------------------------------

Compared with that in the normal group, a greater proportion of the patients in the hypofibrinogenaemia group developed coagulopathy (*p* \< 0.001) and required additional blood products (*p* \< 0.001), but there was no significant difference in the incidence of jaundice (*p* = 0.407), severe bleeding (*p* = 0.129), and 28-day ICU mortality rate (*p* = 0.444). Moreover, the patients with hypofibrinogenaemia had an increased ICU stay duration after starting tigecycline (19 (10--31) vs. 6 (3.25--16.75) days, *p* \< 0.001) and an increased total ICU stay duration (30 (19--48) vs. 13 (5--23) days, *p* = 0.040). Moreover, we found that patients in our study had an increased 28-day ICU mortality rate (52.1% in the hypofibrinogenaemia group and 58.9% in the normal group; Table [4](#Tab4){ref-type="table"}).Table 4Clinical complications and outcomes of patients with severe infections treated with tigecycline in ICUVariableHypofibrinogenaemia groups (*n* = 71)Normal groups (*n* = 56)OR95% CI*p*Coagulopathy (%)49 (69)19 (33.9)4.3372.054--9.161\< 0.001Jaundice (%)17 (23.9)10 (17.9)1.4480.604--3.4720.407Severe bleeding^\#^ (%)8 (11.3)2 (3.6)3.4290.698--16.8390.129Transfusion blood products (%)42 (68.9)15 (26.8)6.0422.709--13.476\< 0.001Lengths of ICU stay after using tigecycline (days)19 (10--31)6 (3.25--16.75)1.0120.997--1.028\< 0.001Total lengths of ICU stay (days)30 (19--48)13 (5--23)1.0141.001--1.0280.04028-day ICU mortality (%)37 (52.1)33 (58.9)0.7580.374--1.5390.444*OR* odds ratio, *CI* confidence interval, *ICU* intensive care unit

Clinical features of hypofibrinogenaemic patients treated with cefoperazone/sulbactam {#Sec12}
-------------------------------------------------------------------------------------

In the hypofibrinogenaemia group, 30 (42%) patients were treated with cefoperazone/sulbactam, and there was no difference in the incidence of hypofibrinogenaemia between the patients who were and were not treated with cefoperazone/sulbactam. Compared with the patients not treated with cefoperazone/sulbactam, these patients had a higher rate of coagulopathy (*p* = 0.009) and needed more blood products (*p* = 0.003), but there was no difference in the lowest fibrinogen levels, rate of jaundice or severe bleeding, time to hypofibrinogenaemia, or time from discontinuation of tigecycline to normalization of the fibrinogen level (Table [5](#Tab5){ref-type="table"}).Table 5Clinical symptoms of patients treated with cefoperazone/sulbactam in the hypofibrinogenaemia groupVariableTigecycline + CPZ/SAM (*n* = 30)Tigecycline ± others (*n* = 41)OR95% CI*p*Sex (male, *n* (%))25 (83.3)30 (73.2)1.8330.562--5.9840.315Age (years) (mean ± SD)67.20 ± 14.4661.17 ± 16.131.0270.994--1.0610.113Index when starting to use tigecycline  SOFA scores9.97 ± 5.989.22 ± 6.411.0200.945--1.0100.614  APACHE II scores12.17 ± 5.8811.56 ± 6.481.0160.941--1.0970.682  Fibrinogen level (g/L)3.840 ± 1.513.966 ± 1.360.9370.667--1.3160.706Organ function when starting to use tigecycline  Respiratory failure (%)26 (86.7)35 (85.4)1.1140.285--4.3550.876  Shock (%)14 (46.7)13 (31.7)1.8850.712--4.9880.202  KidneyAKI (%)16 (53.3)14 (34.1)2.2040.840--5.7850.108CRRT (%)8 (26.7)12 (29.3)0.8790.307--2.5170.810  LiverALB (g/L)32.53 ± 3.7233.08 ± 5.300.9740.877--1.0820.624TB (μmol/L)19 (10.5--41.75)16 (10--25.75)1.0060.991--1.0210.413DB (μmol/L)11.5 (6--26)7 (4--17.25)1.0090.990--1.0290.351INR1.25 (1.15--1.36)1.26 (1.16--1.36)1.4570.241--8.8030.682Infection index when starting to use tigecycline  WBC (× 10E9)\< 4 (%)330.6500.311--1.3580.4484--10 (%)1414\> 10 (%)1324  Neutrophil (%)88.78 ± 7.5888.21 ± 6.190.9900.923--1.0620.787  CRP (mg/L)117.55 ± 59.09117.18 ± 76.201.0000.993--1.0070.982  PCT (ng/mL)5.97 ± 8.587.29 ± 17.540.9930.958--1.0300.716Infected site  Bloodstream infection (%)12 (40)13 (31.7)1.4360.54--3.840.471  Pneumonia (%)21 (70)25 (61)1.4930.55--4.070.433  Intracranial infection (%)3 (10)1 (2.4)4.4440.44--45.010.207  Intra-abdominal infection (%)8 (26.7)8 (19.5)1.500.49--4.590.477  Skin infection (%)1 (3.3)1 (2.4)1.3790.83--22.970.823  Urinary tract infection (%)1 (3.3)4 (9.8)0.320.03--3.010.318  Empirical antibacterial therapy (%)1 (3.3)5 (12.2)0.2480.03--2.250.215  Two or more than (%)14 (46.7)13 (31.7)1.8850.712--4.9880.202Pathogenic microorganism  *Acinetobacter baumannii* (%)14 (46.7)14 (34.1)1.6870.643--4.4290.288  *Klebsiella pneumoniae* (%)17 (56.7)17 (41.5)1.8460.712--4.7860.207  *Burkholderia cepacia* (%)2 (6.7)3 (7.3)0.9050.142--5.7810.916  *Pseudomonas maltophilia* (%)4 (13.3)2 (4.9)3.0000.512--17.5850.223  Others (%)10 (33.3)14 (34.1)0.9640.356--2.6120.943  Two or more than (%)10 (33.3)13 (31.7)1.2470.462--3.3630.663Therapeutic regimen  Loading dose50 mg (%)4 (13.3)8 (19.5)0.6350.172--2.3420.493100 mg or more than (%)26 (87)33 (80.4)0.6350.172--2.3420.493  Maintenance dose50 mg Q12H (%)11 (36.7)22 (53.7)1.3260.728--2.4170.357100 mg Q12H (%)11 (36.7)11 (26.8)50 or 100 mg Q12H (%)8 (26.7)8 (19.5)  Treatment duration11.5 (8--18)11 (8--14)1.0690.995--1.1480.068Clinical features  The lowest fibrinogen levels (g/L)1.12 ± 0.431.16 ± 0.290.7290.189--2.8210.648  Day to be hypofibrinogenaemia after using tigecycline (days)6 (4--8.25)5 (4--7)1.0740.954--1.2190.236  Day to be normalized after discontinuation of tigecycline (days)3 (2.25--3.75)4 (3--5)0.7960.506--1.2550.326  Coagulopathy (%)26 (86.7)23 (56.1)5.0871.502--17.2320.009  Jaundice (%)9 (30)8 (19.5)1.7680.589--5.3020.309  Severe bleeding (%)5 (16.7)2 (4.9)2.5330.555--11.5570.230  Transfusion blood products (%)24 (80)18 (43.9)5.1111.724--15.1510.003*OR* odds ratio, *CI* confidence interval, *SOFA* Sequential Organ Failure Assessment, *APACHE* Acute Physiology and Chronic Health Evaluation, *AKI* acute kidney injury, *CRRT* continuous renal replacement therapy, *ALB* albumin, *ALT* alanine transaminase, *TB* total bilirubin, *DB* direct bilirubin, *INR* international normalized ratio, *WBC* white blood cells, *CRP* C-reactive protein, *PCT* procalcitonin, *CPZ/SAM* cefoperazone/sulbactam

Discussion {#Sec13}
==========

The manufacturer lists gastrointestinal symptoms as the most common adverse reaction to tigecycline, and atypical adverse reactions involve the blood and lymphatic system (incidence, 2%), APTT and PT prolongation, an increased eosinophil count, an increased INR, and a decreased platelet count \[[@CR5]\]. Several severe cases of tigecycline-associated coagulopathy and hypofibrinogenaemia have been reported.

Fibrinogen is a glycosylated acute-phase protein synthesized by liver parenchymal cells that has a half-life of 3 to 4 days. The normal range of the fibrinogen level in the bloodstream is 2 to 4 g/L. Hypofibrinogenaemia can occur in patients with chronic inherited diseases such as afibrinogenaemia, dysfibrinogenaemia, or hypodysfibrinogenaemia \[[@CR25]\]; patients with acquired hepatic dysfunction, such as cirrhosis, hepatitis, and metastatic hepatoma \[[@CR26]\]; and patients with severe malnutrition. Acute hypofibrinogenaemia is associated with disseminated intravascular coagulation (DIC), severe sepsis, malignancy, and drug administration (valproic acid, synthetic adrenocorticotropic hormone (ACTH), prednisolone, [l]{.smallcaps}-asparaginase, allopurinol, and tigecycline) \[[@CR4]\]. In this study, there was no difference in medical history, age, sex, or infection indices or liver function at the time of tigecycline initiation between the two groups. Indeed, the fibrinogen levels of 42 out of 51 patients recovered after the discontinuation of tigecycline. Therefore, all of the cases of hypofibrinogenaemia were most likely caused by tigecycline.

In the hypofibrinogenaemia group, 71 patients (56%) developed hypofibrinogenaemia at a median (25--75th percentile) of 6 (4--8) days. This is in agreement with prior reports: Sabanis et al. \[[@CR4]\] showed that coagulation parameters worsened markedly on day 7 after the start of tigecycline, and Rossitto et al. \[[@CR7]\] and Duran et al. \[[@CR11]\] demonstrated that hypofibrinogenaemia developed on days 5 and 10, respectively. Routsi et al. \[[@CR7]\], in a study of 45 ICU patients on tigecycline, reported that a progressive increase in the plasma fibrinogen concentration occurred from day 0 to 7 and in two case reports on days 2 and 19 \[[@CR4], [@CR10]\]. In this study, the fibrinogen level of 82% of the patients (42/52) returned to within the normal range in a median of 3 (3--5) days. This is also in accord with previous cases \[[@CR4], [@CR7]--[@CR11]\]. Hypofibrinogenaemia induced by tigecycline has not been analyzed in large clinical trials, and the risk factors for tigecycline-associated hypofibrinogenaemia are unclear. Only two clinical studies \[[@CR5], [@CR12]\] have reported a significantly decreased fibrinogen level in patients treated with a high dose, and Wu et al. \[[@CR10]\] showed that female sex, renal insufficiency, and a high dose may be risk factors for adverse reactions in patients with tigecycline-associated coagulation disorder. Univariate analyses in our study also showed that the maintenance dose (*p* = 0.027) was a risk factor for hypofibrinogenaemia, and a loading dose of 50 mg (*p* = 0.045) and maintenance dose of 50 mg Q12H (*p* = 0.016) may protect against hypofibrinogenaemia.

Although a maintenance dose of 50 mg Q12H may be a protective factor for normal fibrinogen levels, the pharmacokinetic/pharmacodynamic properties of tigecycline suggest that high-dose (HD) (100 mg Q12H) regimens may be more effective than low-dose (LD) (50 mg Q12H) regimens. Cunha and colleagues first reported that HD tigecycline is effective and it became the preferred dosing regimen for treating serious systemic infections due to susceptible and MDR pathogens \[[@CR27]\]; thereafter, some studies confirmed HD tigecycline is associated with improved outcomes (including clinical outcome, microbiological eradication rate, increased survival time, and decreased mortality) compared with LD tigecycline \[[@CR28]--[@CR32]\]*.* However, a retrospective study including 134 patients who were diagnosed with ventilator-associated pneumonia (VAP) showed no significant difference in the incidence of 28-day mortality among different dose groups (LD, HD, and non-standard HD groups) \[[@CR33]\]. In addition, a meta-analysis including 17 studies (11 studies from China, 3 published in English, and 8 in Chinese) showed that all-cause mortality for patients treated with HD tigecycline was significantly lower than that for patients treated with LD tigecycline; however, subgroup analyses by country showed no significant difference in the non-Chinese studies. The microbiological eradication rate of the HD regimen was also significantly higher than that of the LD regimen, whereas a non-Chinese study presented a negative result in the subgroup analyses \[[@CR34]\]. Hence, both efficacy and safety should be taken into account when a physician chooses tigecycline as an antibacterial agent.

In the multivariate analysis, intra-abdominal infection was found to be related to hypofibrinogenaemia (*p* = 0.008) but not pathogenic bacteria. This may be linked to the mechanism by which tigecycline induces hypofibrinogenaemia. Antibiotics in general are associated with coagulation disorders, as they reduce the microflora of the colon and the distal ileum, which synthesize vitamin K~2~ (menaquinone) \[[@CR35]\]. The underlying mechanism for this effect is unclear. Moreover, intra-abdominal infection can further reduce the intestinal microflora.

Compared with the mortality due to sepsis in patients in a prior study \[[@CR36]\], patients in our study had an increased 28-day ICU mortality rate (52.1% vs. 58.9%). Increased SOFA scores (9.54 ± 6.20 vs. 10.95 ± 7.23) and multiple or extensively drug-resistant bacteria (40.9% and 48.8% *Acinetobacter baumannii* and *Klebsiella pneumoniae*, respectively) may be an explanation; moreover, 41 patients suffering from bloodstream infection may be another reason.

Sulbactam enhances the activity of cefoperazone and is used in cases of moderate-to-severe infection \[[@CR37], [@CR38]\]. Long-term high-dose use of cefoperazone/sulbactam can cause vitamin K deficiency, leading to reduced levels of vitamin K--dependent coagulation factors and resulting in coagulation disorder. Although alteration of the microflora of the colon and the distal ileum, which synthesize vitamin K~2~, is a commonly cited mechanism of antibiotic-associated coagulopathy, the mechanism of hypofibrinogenaemia is unclear. It has been suggested that the tigecycline-mediated inhibition of cytokines interferes with fibrinogen production \[[@CR9]\]. Sabanis et al. \[[@CR4]\] showed that coagulopathy induced by the inhibition of MK-producing bacteria or by a direct effect on hepatic vitamin K activation and impaired liver function is implicated in the fibrinogen-level reduction. Furthermore, they recommended that the mechanisms be investigated, focusing on the role of genetic factors \[[@CR4]\]. Therefore, further studies of the mechanisms underlying tigecycline-associated hypofibrinogenaemia are warranted.

This study has several limitations. First, it was a retrospective case--control study and thus might have been influenced by selection bias. Second, we analyzed all pathogenic bacteria as a group but not individually, even though the presence of pathogenic bacteria is not a risk factor; a confounding bias might have been avoided if we had analyzed the presence of individual bacterial species in the study. Third, the heterogeneity of ICU patients limited the statistical analysis; further randomized controlled trials with larger cohorts or animal studies are warranted. Despite these limitations, we identified several clinical features and risk factors of tigecycline-associated hypofibrinogenaemia, which will facilitate further research in this field.

Hypofibrinogenaemia is an uncommon and life-threatening side effect of tigecycline treatment and is easily overlooked. We suggest that patients treated with tigecycline should be monitored for changes in the INR, PT, APTT, and fibrinogen level, as well as adverse reactions, to avoid severe, life-threatening disturbances of coagulation.
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